Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$36.93M+114.40%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carrie A. Lachance
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 467
- Beta
- 1.50
- Country
- US
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 5.25
Financials
Revenue
$36.93M+114.4%Net Income
$3.23M+5669.6%EBITDA
$4.13M+27.8%Free Cash Flow
$8.37M+306.9%EPS (diluted)
$0.15+6150.0%Shares Outstanding (diluted)
20.93M-9.0%Operating Expenses
$17.09MCash & Debt
$964.0KReturn of Capital
$4.16MRevenue by Segment (annual)
$150.63MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $143.44M | $6.63M | $0.32 |
| 2024 | $134.86M | $2.35M | $0.11 |
| 2023 | $125.78M | $872.0K | $0.04 |
| 2022 | $109.91M | $18.0K | $0.00 |
| 2021 | $102.38M | $1.42M | $0.07 |
| 2020 | $97.39M | $17.33M | $0.86 |
| 2019 | $81.11M | $1.36M | $0.07 |
| 2018 | $67.14M | $-1.09M | $-0.05 |
| 2017 | $71.08M | $-20.71M | $-0.91 |
| 2016 | $70.50M | $-222.0K | $-0.01 |
| 2015 | $72.13M | $3.74M | $0.17 |
| 2014 | $66.49M | $3.36M | $0.15 |
| 2013 | $62.28M | $1.67M | $0.08 |
| 2012 | $58.83M | $-1.49M | $-0.07 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.47
- Implied price
- $13.20
- Return from $12.69
- 0.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $6.56 — -48.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| -2.0% | -14.5% | -11.3% | -8.5% | -6.1% | -3.8% |
| 3.0% | -10.1% | -6.8% | -3.9% | -1.3% | 1.1% |
| 8.0% | -5.8% | -2.3% | 0.8% | 3.5% | 6.0% |
| 13.0% | -1.4% | 2.3% | 5.5% | 8.3% | 10.9% |
| 18.0% | 3.0% | 6.8% | 10.1% | 13.1% | 15.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·5h ago·Positive
InfuSystem Holdings, Inc. (INFU) Discusses Business Overview and Growth Strategy with Focus on Patient-First Approach Transcript InfuSystem Holdings, Inc. (INFU) Discusses Business Overview and Growth Strategy with Focus on Patient-First Approach Transcript
View source ↗ - Newsbusinesswire.com·7d ago·Neutral
InfuSystem to Host Investor Webcast on September 24, 2026 ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Host Investor Webcast on September 24, 2026.
View source ↗
Earnings
Tue, Nov 3(in 6 weeks)
Consensus estimate $0.13 per share
Typical surprise +42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.15 vs $0.10beat
- Thu, May 7$0.05 vs $0.04beat
- Tue, Feb 24$0.10 vs $0.07beat
- Tue, Nov 4$0.11 vs $0.08beat
- Tue, Aug 5$0.12 vs $0.03beat
- Thu, May 8$-0.01 vs $-0.03beat
Estimates and results for INFU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INFU officers and directors.
- Bought
- $227k
- Sold
- $420k
10 trades
4 trades
- Lachance Carriebought
- Gendron Paul Andrewbought
- Lachance Carriebought
- Steele Barry Gbought
- Steele Barry Gbought
- Shuda Scottsold
- Eichenbaum Kenneth D.bought
- Hundzinski Ronald Tbought
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INFU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.